Conference Documentation: Advances in Hypertension & Cardiovascular Therapeutics

Published by: SMI Publishing, Ltd

Published: May. 29, 2002

Table of Contents

Day 1

9.00 Registration and Coffee

9.30 Chairman's Opening Remarks

Dr Tim Auton, Head of Biomedical Statistics, Protherics.

9.40 ANTIHYPERTENSIVE MARKET DYNAMICS

An overview

Antihypertensive drugs: size, growth and market drivers

ACE vs AIIRBs: the battle for sales supremacy

Niche hypertensive populations: diagnosis, treatment rates and combination therapy

Benefits beyond blood pressure lowering

What’s in the pipeline?

Forecasts for the market to 2008

Ms Helen Smith, Director, Cardiovascular & Diabetes Services, Datamonitor.

10.20 HYPERTENSION: MORE THAN JUST NUMBERS

Current issues for developers

The scale of the problem: the global burden of hypertension

When is BP too high? How low to treat

Is arrogance or ignorance the problem with achieving control?

The importance of hypertension therapies - outcomes

Complications of hypertension - end-organ disease

Issues for further development in hypertension

Dr Milton Pressler, Exec Director, Cardiovascular Clinical Research, Pfizer Ann Arbot Labs.

11.00 Morning Coffee

11.20 SPECIAL PATIENT POPULATIONS IN HYPERTENSION TRIALS

Lessons to be learnt

Hypertension studies in the elderly

Paediatric populations

Renal impairment

Hepatic impairment

Mixed patient populations - eg: diabetics with arthritis and hypertension

Study design considerations, including duration of study, dropped dose design

Compliance

Dr Peter Djuric, Director, Cardiovascular Clinical Research, Quintiles (UK) Ltd.

12.00 NEW TECHNIQUES TO ASSESS SURROGATE MARKERS

Endothelial Function and Vascular Stiffness as Vascular Targets

Endothelial function and vascular stiffness as targets for therapy

Limitations of current methods

New methods

Dr Philip Chowienczyk, Senior Lecturer in Clinical Pharmacology, Kings College London.

12.40 Lunch

2.00 ENDOTHELIN RECEPTOR ANTAGONISTS IN HYPERTENSION

The potential role of endothelin antagonists for treating hypertension

Pathophysiological role of endothelin in hypertension · Vasoconstriction · Vascular remodelling

Development of selective ETA receptor antagonists

Clinical efficacy of endothelin antagonists

Opportunities for new drugs in an already crowded market

Dr Tommy Brock, V.P., Texas Biotechnology Corporation.

2.40 AN ANGIOTENSIN IMMUNOTHERAPEUTIC VACCINE FOR THE TREATMENT OF HYPERTENSION

Issues for consideration

Advantages of an immunotherapeutic approach to hypertension

Mechanism of action

Summary of animal pharmacology results

Summary of early phase clinical data

Dr Tim Auton, Head of Biomedical Statistics, Protherics.

3.20 Afternoon Tea

3.40 PULMONARY ARTERIAL HYPERTENSION (PAH)

Targeting the disease

PAH - the disease

The disease target

Current therapeutic modalities

Targeted inhalation therapy

Mr David Crockford, VP Corp Development & Scientific Affairs, Profile Therapeutics.

4.20 LEGAL ISSUES

Patent and regulatory issues

Regulatory guidelines for anti-hypertensives

Obtaining regulatory approval

Safety and clinical efficacy

Patent expiry/data exclusivity issues-keeping generics at bay

Improving the regulatory process

Ms Archana Daniels, Solicitor, Bristows.

5.00 Chairman's Closing Remarks and Close of Day One

Day 2

8.30 Re-registration and Coffee

9.00 Chairman's Opening Remarks

Dr Desmond Fitzgerald, Consultant in Pharmaceutical Medicine, Materia Medica.

9.10 VASCULAR PROTECTANTS

A new clinically validated target for atherosclerosis therapy and prevention of restenosis after PCI

Review of biology and chemistry of vascular protectants

Review of top line animal pharmacology

Top line clinical trial results that validate vascular (v-) protectants as a new target for drug development

Next steps

Dr Mitchell Glass, Senior Vice President, AtheroGenics, Inc..

10.20 THE DISCOVERY OF ACE INHIBITORS

Are there lessons for current cardiovascular research?

Why did exploitation take so long?

Is target validation any better today?

Relevance to decision taking in research

Lessons of possible relevance

Dr Desmond Fitzgerald, Consultant in Pharmaceutical Medicine, Materia Medica.

11.00 Morning Coffee

11.20 HYPERLIPIDEMIA

Where To Next?

Hyperlipidemia Market - Current Status

Medical Practice

Clinical Unmet Needs

Statin Challengers

Winners in 2010

Dr Nicola Maidwell, Analyst, Decision Resources.

12.00 TRANSLATION OF GENOMIC FINDINGS INTO CARDIOVASCULAR THERAPEUTICS

Gene Targets

Single-nucleotide polymorphism (SNP) and common genetic diseases

Genome wide SNP association studies for complex disease gene discovery

Target validation using human genetics

Novel gene targets for cardiovascular therapeutics

Developmental strategies for gene targets

Dr Michael Shi, Senior Director, Target Discovery, Sequenom, Inc..

12.40 Lunch

2.00 GENE TRANSFER TO INCREASE MYOCARDIAL CONTRACTILITY IN HEART FAILURE

Gene transfer

Rationale

Adenylate cyclase gene transfer

FGF.4 Gene transfer in heart failure

Clinical trials of gene transfer

Dr Kirk Hammond, Scienfic Founder, University of California San Diego.

2.40 THROMBOSIS

New advances in a rapidly expanding blockbuster market

Spectrum of disease and need for chronic therapy

Uses of currently marketed agents and their limitations

Recent developments giving rise to new classes of agents in development

Direct Thrombin Inhibitors - finally delivering on a long-held promise?

Ms Katharine Harris, Head of Corporate Communications, Trigen Ltd.

3.20 Afternoon Tea

3.40 PAEDIATRIC CLINICAL STUDIES FOR LABELING AND EXCLUSIVITY

Issues

Regulatory issues for consideration-US

Regulatory Issues for consideration-Europe

Trial design issues

Ethical considerations

Consent issues

Dosing for children; results from trials

Dr Margo Schleman, Executive Director Clinical Research, AstraZeneca.

4.20 DEFENDING AGAINST COMPETITION

Successful branding

Using branding to defend against generic competition

Corporate branding

Using branding to your advantage

Portfolio management

Mr Tom Blackett, Group Deputy Chairman, Interbrand.

5.00 Chairman's Closing Remarks and Close of Conference

Abstract

What the information package includes:

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.